Peroxisome Proliferator-Activated Receptor-γNovel Therapeutic Target Linking Adiposity, Insulin Resistance, and Atherosclerosis

被引：0
作者：
Alper Kepez
Ali Oto
Selcuk Dagdelen
机构：
[1] Hacettepe University,Faculty of Medicine Cardiology Department
[2] Hacettepe University Faculty of Medicine,Endocrinology Department
来源：
BioDrugs | 2006年 / 20卷
关键词：
Insulin Resistance; Adipose Tissue; Rosiglitazone; White Adipose Tissue; Hepatic Steatosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Insulin resistance and obesity is a common health problem in the industrialized world. As a result of the availability of high-calorie food and a reduction in energy expenditure, maladaptive metabolic processes may interfere with the action of insulin and increase susceptibility for the development of atherosclerotic cardiovascular diseases. With the advent of peroxisome proliferator-activated receptors (PPARs), the mechanisms of this maladaptation and its relationship to insulin resistance syndrome components have become less obscure, promising new therapeutic approaches for this common problem. In this review we first focus on the molecular structure and cellular mechanisms of action of these receptors and then discuss how PPAR-γ, a PPAR isoform, provides a link between adiposity, insulin resistance, and atherosclerosis.
引用
收藏
页码：121 / 135
页数：14
相关论文
共 447 条
  • [1] Mokdad A.H.(2003)Prevalence of obesity, diabetes, and obesity related health risk factors 2001 JAMA 289 76-9
  • [2] Ford E.S.(2002)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 3143-421
  • [3] Bowman B.A.(2002)The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2709-16
  • [4] Lakka H.M.(2003)C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: a 8-year follow-up of 14 719 initially healthy American women Circulation 107 391-7
  • [5] Laaksonen D.E.(2003)Treatment for patients with the metabolic syndrome Am J Cardiol 91 29E-39E
  • [6] Lakka T.A.(2001)The pleiotropic functions of peroxisome proliferator-activated receptor y J Mol Med 79 30-47
  • [7] Ridker P.M.(1995)An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor y (PPAR-γ) J Biol Chem 270 12953-6
  • [8] Buring J.E.(1990)Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 645-50
  • [9] Cook N.R.(1992)Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors Cell 68 879-87
  • [10] Ginsberg H.N.(1994)Differential expression and activation of family murine peroxisome proliferator-activated receptors Proc Natl Acad sci US A 91 7355-9
12345678910